AIDX.TO Healwell AI TSX at C$0.88 intraday 12 Mar 2026: AI growth vs weak cash flow

AIDX.TO stock trades at C$0.88 intraday on the TSX on 12 Mar 2026, down 1.12% from yesterday. Volume is 118,925 shares versus an average of 562,279, so liquidity is light today. The company reports earnings on 19 Mar 2026, creating a near-term catalyst. We examine fundamentals, technicals and our AI-driven forecast for Healwell AI Inc. (AIDX.TO) and frame price targets for investors.

AIDX.TO stock: quick snapshot and market context

Healwell AI Inc. (AIDX.TO) is a Toronto-listed healthcare technology company focused on AI decision support. The current market cap is C$250.56M and shares outstanding are 278,397,768. The 52-week range is C$0.58–C$1.81. The healthcare sector has underperformed year-to-date, and investors are weighing AI opportunity against weak operating cash flows.

Fundamentals and valuation: revenue, margins and ratios

AIDX.TO shows trailing EPS of -0.23 and a negative PE of -3.91, reflecting losses. Price-to-sales is 2.47 and price-to-book is 1.76. Revenue per share is 0.42 and book value per share is 0.52. The current ratio is 0.85, below the healthcare sector average near 1.14, signaling tighter short-term liquidity. These metrics point to valuation that rewards growth but flags cash conversion and margin risk.

Technicals and trading signals for AIDX.TO stock

Short-term momentum is constructive. RSI is 64.34, MACD histogram is positive, and ADX at 38.77 signals a strong trend. Day range is C$0.87–C$0.90 with average 50-day price C$0.79 and 200-day C$1.17. On balance volume is negative and relative volume is 0.54, so follow-through needs higher participation. Traders should watch a break above C$0.96 (Bollinger upper) for upside acceleration.

Meyka AI grade, forecast and model projection

Meyka AI rates AIDX.TO with a score out of 100: 62.24 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of C$0.65, a quarterly price of C$0.72, and a yearly price of C$0.40. Versus the current C$0.88, monthly implies -26.14% downside, quarterly implies -18.18%, and yearly implies -54.55%. Forecasts are model-based projections and not guarantees. See company site for filings Healwell AI and our platform page for live updates AIDX.TO on Meyka.

Catalysts, risks and sector comparison for AIDX.TO stock

Near-term catalysts include the 19 Mar 2026 earnings release and ongoing partnerships with WELL Health Technologies. Key risks are negative operating cash flow per share (-0.10), tight current ratio (0.85), and persistent net losses. The healthcare sector average ROE is around 1.51%; AIDX.TO’s ROE is -56.89%, showing underperformance versus peers. Positive catalysts would be margin improvement, larger enterprise contracts, or improved cash conversion.

Price targets and trading strategy for AI-focused investors

We set scenario targets to aid planning. A base target is C$1.20 (+36.36% vs C$0.88). A bull target is C$1.80 (near year high; +104.55%). A bear target is C$0.60 (-31.82%). For short-term traders, watch volume confirmation above C$0.96. For longer-term AI investors, require signs of free cash flow improvement and revenue growth above the current 4.33% annual revenue growth rate before adding size.

Final Thoughts

AIDX.TO stock trades at C$0.88 intraday on TSX on 12 Mar 2026, with light volume and mixed signals. Fundamentals show a meaningful AI growth opportunity but weak cash flow and negative EPS of -0.23. Technicals favor momentum, yet average volume is below historic levels. Meyka AI’s model projects shorter-term downside to C$0.72–C$0.65 and a yearly projection near C$0.40, which implies material downside versus today. Our base price target of C$1.20 assumes recurring contract wins and improved margins. Investors should treat the stock as speculative AI-exposure inside healthcare and watch the 19 Mar 2026 earnings for revenue visibility. Meyka AI provides this as AI-powered market analysis; forecasts and the grade are model outputs and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.